Evidence / Crisafulli et al. · 2004
Genistein in early postmenopause
Selected research. Study type, product relevance and limitations are shown separately.
Editorial study summary
- Study type
- Randomized, double-blind human trial with active and placebo controls.
- Product relevance
- Ingredient evidence for a separate genistein intervention.
- Sample or population
- 90 postmenopausal women aged 47–57.
- Studied dose
- 54 mg/day of genistein, estrogen-progestogen therapy, or placebo.
- Duration
- 1 year.
- Finding
- The genistein group reported fewer daily hot flushes than placebo at the reported follow-ups. The abstract reports no uterine side effect in the study.
- Limitations
- A small trial using a different intervention. It does not establish long-term safety or equivalence to the active comparator.
- Study quality
- Three-arm controlled trial with symptom and ultrasound measures. Editorial review was limited to the abstract. No formal risk-of-bias rating was assigned.
- Funding and disclosures
- Funding and conflicts were not verified from the abstract.
The studies discussed here examine ingredients or other formulations. They do not establish results for this DR.MORGAN finished product.